

Attorney Docket Number 0 98393 US

**In the Specification:**

On page 1, prior to paragraph 1, please insert:

This application is a 35 U.S.C. 371 National Phase application of PCT/EP99/05050 filed July 16, 1999, which is based for priority on European Application EP 98202470.5 filed July 23, 1998.

On page 10, replace lines 1-15 with the following:

~~Legends to the figures~~ Brief Description of the Figures

**Figure 1**

Figure 1a, b, c. Cross reactivity of three, different, HC gp-39-specific hybridomas (8B12, 14G11, 20H5) with YKL-39 (266-278)

(CVR0271B = HC gp-39 (263-275), KV0432B = YKL-39 (266-278), CC0332B = Chi (269-282), KV0431A = YKL-39 (262-274). HCDA.8B12.1D8, 14G11.1H7 and 20H5.4F6.2F6 are HLA-DRB1\*0401-restricted hybridomas specific for HC gp-39 (263-275). Activation of T-cell hybridomas is expressed as IL-2 production.

**Figure 2**

Figure 2 2a, 2b, 2c In vivo tolerization with HC gp-39 (263-275) or YKL-39 (266-278)

Balb/c mice were tolerized by intranasal application of

Attorney Docket Number 0 98393 US

50, 10 or 2 micrograms of HC gp-39 (263-275), SEQ ID NO: 3,  
(Fig. 2b) or YKL-39 (266-278) (Fig. 2c) followed by immunization  
with HC gp-39 (263-275). Mice that were pretreated with saline  
or that were left untreated were included as controls (Fig. 2a).